Gynaecologic Oncology Society of Kenya (GOSK) clinical management protocol for uterine sarcoma in Kenya - 2026
DOI:
https://doi.org/10.59692/prar0621Keywords:
Endometrial stromal sarcoma, Kenya, Leiomyosarcoma, Uterine sarcomaAbstract
Objective: To establish a standardized, evidence-based approach to the management of uterine sarcoma in Kenya through the adaptation and contextualization of relevant international clinical practice guidelines.
Methods: The protocol was developed using a guideline adaptation approach to align recommendations from international clinical practice guidelines with Kenya’s healthcare system and resource context. A multidisciplinary panel comprising gynecologic oncologists, pathologists, radiologists, oncology nurses, pharmacists, radiation oncologists, public health specialists, and patient representatives participated in the process. Panel members received technical training from the University of Nairobi and Kenyatta National Hospital on evidence-based guideline adaptation, including standardized appraisal and contextualization to local needs. A systematic search of PubMed and Google Scholar identified four guidelines for independent appraisal using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument: the British Gynaecological Cancer Society (BGCS), National Comprehensive Cancer Network (NCCN), European Society of Gynaecological Oncology (ESGO), and European Society for Medical Oncology (ESMO) guidelines. The selected guidance was reviewed and contextualized to Kenya’s healthcare and resource setting.
Results: The protocol addresses the diagnosis, referral, staging, histopathological assessment, preoperative investigations, and surgical management of uterine sarcoma. It also covers chemotherapy, radiotherapy, systemic treatment, risk-adapted management, recurrent disease, post-treatment surveillance, and supportive and palliative care. Molecular profiling and emerging treatment approaches are addressed where clinically appropriate and available.
Recommendations: The protocol provides a standardized framework for the diagnosis, histology-specific management, treatment, and surveillance of uterine sarcoma in Kenya. It is intended to support consistent clinical decision-making, multidisciplinary care, appropriate use of available resources, and equitable access to evidence-informed management.
References
1. Cheng G, Hu Y, Gong Y. Clinical manifestations and prognosis of unexpected uterine sarcoma. BMC Womens Health. 2022;22(1):495.
2. Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl 2):51–58.
3. Forney JP, Buschbaum HJ. Classifying, staging, and treating uterine sarcomas. Contemp Ob Gyn. 1981;18(3):47–69.
4. Gershenson D, et al. Gynecologic Cancer: Controversies in Management. 3rd ed. Churchill Livingstone; 2004.
5. Bergman L, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet. 2000;356(9233):881–7.
6. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94(2):256–66.
7. Wickerham DL, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20(11):2758–60.
8. Major FJ, et al. Prognostic factors in early-stage uterine sarcoma. Cancer. 1993;71(4 Suppl):1702–9.
9. Oláh KS, et al. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumors. Br J Obstet Gynaecol. 1992;99(7):590–4.
10. Omura GA, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas. J Clin Oncol. 1985;3(9):1240–5.
11. Tavassoli FA, Devilee P. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. IARC Press; 2004.
12. Evans HL, et al. Smooth muscle neoplasms of the uterus. Cancer. 1988;62(10):2437–44.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 2025. Plymouth Meeting (PA): NCCN; 2025.
14. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–1365.
15. Morrison J, Balega J, Buckley L, et al. British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2022;270:50–89.
16. Ray-Coquard I, Casali PG, Croce S, et al. Uterine sarcomas: ESGO/EURACAN/GEIS guidelines for medical oncologists. Int J Gynecol Cancer. 2023;33(11):1655–1678.
17. Korir A, Okerosi N, Ronoh V, Mutuma G, Parkin M. Incidence of cancer in Nairobi, Kenya (2004–2008). Int J Cancer. 2015;137(9):2053–2059.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr. Marion Diana, Prof. Jacqueline J. Chesang', Dr. Benjamin E. Odongo, Dr. Millicent S. Masinde, Dr. Wycliffe Musalia, Dr. Alfred Mokomba, Prof. Rose J. Kosgei, Dr. Isaac M. Maingi, Dr. Bruce O. Semo, Dr. Steven M. Ibua, Dr. Simon M. Gitau, Dr. Gideon M. Mutua, Dr. Stella N. Njenga, Dr. Naomi N. Sitati, Dr. Anwar Z. Mohamed, Prof. Eunice J. Cheserem, Dr. Margaret K. Kilonzo, Dr. Innocent O. Maranga

This work is licensed under a Creative Commons Attribution 4.0 International License.
